Applications of computer-aided approaches in the development of hepatitis C antiviral agents

Expert Opinion on Drug Discovery

Volumn 12, Issue 4, 2017, Pages 407-425

  Ganesan, Aravindhan ^a   Barakat, Khaled ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

binding free energy; computer aided drug design; direct acting agents; drug discovery; hepatitis C virus; Molecular dynamics; protein flexibility; QSAR

Indexed keywords

ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PROTEOME; LIGAND;

ANTIVIRAL RESISTANCE; COMPUTER AIDED DESIGN; COMPUTER MODEL; DRUG DESIGN; DRUG SCREENING; GENETIC VARIATION; HEPATITIS C; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REPLICON; REVIEW; VIRTUAL REALITY; COMPUTER SIMULATION; DRUG EFFECTS; HEPACIVIRUS; VIROLOGY;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION;

EID: 85015416301     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1291628     Document Type: Review

References (144)

1. Weiser BM, Tellinghuisen TL., Structural biology of the hepatitis C virus proteins. Drug Discov Today Technol. 2012;9:e195–e204.
2. Houghton M. Discovery of the hepatitis C virus. Liver Int. 2009;29:82–88.
3. World Health Organization. Hepatitis C 2016 [cited 2016 July]. Available from:http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362.• This study reports the discovery of HCV for the first time, which led to the development of several HCV vaccines.
5. Friedman RM, Contente S. Treatment of hepatitis C infections with interferon:a historical perspective. Hepat res treat. 2010;2010:323926.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon Alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492.
7. Kozlowski A, Milton Harris J. Improvements in protein PEGylation:pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72:217–224.
8. Poordad F, Dieterich D. Treating hepatitis C:current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19:449–464.
9. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus Ribavirin with or without peginterferon-alfa in patients with hepatitis C Virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149:1462–1470.
10. McConachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy:a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol. 2016;9:287–302.•• This is a very recent review that discusses in detail the pertinent clinical data, pharmacology, and pharmacokinetics of some of the selected direct acting anti-HCV agents.
11. U. S. Food Drug Administration. FDA approves Epclusa for treatment of chronic hepatitis C virus infection 2016[cited 2016 28 June]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm.
12. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer. 2016;11:24.
13. FFdC E, Teodorico CR, Carlton AT, et al. Computer-assisted analysis of the interactions of macrocyclic inhibitors with wild type and mutant D168A hepatitis C virus NS3 serine protease. Lett Drug Des Discov. 2006;3:17–28.
14. Ontoria JM, Di Marco S, Conte I, et al. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease. J Med Chem. 2004;47:6443–6446.
15. Wei H-Y, Lu C-S, Lin T-H. Exploring the P2 and P3 ligand binding features for Hepatitis C virus NS3 protease using some 3D QSAR techniques. J Mol Graph Model. 2008;26:1131–1144.
16. Xue W, Wang M, Jin X, et al. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A:insights from molecular dynamics simulation, binding free energy calculation and network analysis. Mol Biosyst. 2012;8:2753–2765.
17. Lin MV, King LY, Chung RT. Hepatitis C virus–associated cancer. Annu Rev Pathol. 2015;10:345–370.
18. Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology. 2004;39:5–19.
19. Ashfaq UA, Javed T, Rehman S, et al. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:1–10.
20. Hundt J, Li Z, Liu Q. Post-translational modifications of hepatitis C viral proteins and their biological significance. World J Gastroenterol. 2013;19:8929–8939.
21. Khaliq S, Jahan S, Hassan S. Hepatitis C virus p7:molecular function and importance in hepatitis C virus life cycle and potential antiviral target. Liver Int. 2011;31:606–617.
22. Marcotrigiano J. Progress on new hepatitis C virus targets:NS2 and NS5A. In:Sussman JL, Spadon P, editors. From molecules to medicines:structure of biological macromolecules and its relevance in combating new diseases and bioterrorism. Dordrecht:Springer Netherlands; 2009. p. 121–138.
23. Sklan EH, Glenn JS. HCV NS4B:from obscurity to central stage. In:Tan SL, editor. Hepatitis C Viruses:genomes and molecular biology. Norfolk (UK):Horizon Bioscience; 2006.
24. Wong KA, Worth A, Martin R, et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333–6340.
25. DeMarini DJ, Johnston VK, Konduri M, et al. Intracellular hepatitis C virus RNA-dependent RNA polymerase activity. J Virol Methods. 2003;113:65–68.
26. Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Mol Biol. 1999;6:937–943.
27. Sesmero E, Thorpe IF. Using the hepatitis C virus RNA-dependent RNA polymerase as a model to understand viral polymerase structure, function and dynamics. Viruses. 2015;7:3974–3994.
28. Barakat KH, Law J, Prunotto A, et al. Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design. J Chem Inf Model. 2013;53:3031–3043.
29. Ohno T, Lau JY. The “gold-standard,” accuracy, and the current concepts:hepatitis C virus genotype and viremia. Hepatology. 1996;24:1312–1315.
30. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–973.
31. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon Alfa-2a plus Ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
32. Meeprasert A, Hannongbua S, Rungrotmongkol T. Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus. J Chem Inf Model. 2014;54:1208–1217.
33. Butkiewicz NJ, Wendel M, Zhang R, et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides:identification of sequence and critical residues of NS4A for the cofactor activity. Virology. 1996;225:328–338.
34. Koch JO, Lohmann V, Herian U, et al. In vitroStudies on the activation of the hepatitis C virus NS3 proteinase by the NS4A cofactor. Virology. 1996;221:54–66.
35. Arthitaya M, Thanyada R, Mai Suan L, et al. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus. Curr Pharm Des. 2014;20:3465–3477.
36. Romano KP, Ali A, Royer WE, et al. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proceedings of the National Academy of Sciences. 2010;107:20986–20991.
37. Barbato G, Cicero DO, Nardi MC, et al. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism1. J Mol Biol. 1999;289:371–384.
38. Shiryaev SA, Thomsen ER, Cieplak P, et al. New details of HCV NS3/4A proteinase functionality revealed by a high-throughput cleavage assay. Plos One. 2012;7:e35759.
39. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996;87:343–355.
40. Abian O, Vega S, Jl N, et al. Conformational stability of hepatitis C virus NS3 protease. Biophys J. 2010;99:3811–3820.
41. Thai KM, Dong QH, Nguyen TTL, et al. Computational approaches for the discovery of novel hepatitis C virus NS3/4A and NS5B inhibitors In:Information resources management A, editor. Oncology:breakthroughs in research and practice.Hershey, PA, USA:IGI Global; 2017. 482–518.•• This article is related to the current review and discusses various computational methods employed for the discovery of promising DAAs to target NS3/4A and NS5B enzymes.
42. Johansson A, Hubatsch I, Åkerblom E, et al. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Biorg Med Chem Lett. 2001;11:203–206.
43. Frecer V, Kabeláč M, De Nardi P, et al. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. J Mol Graph Model. 2004;22:209–220.
44. De Francesco R, Steinkühler C. structure and function of the hepatitis C virus NS3-NS4A serine proteinase. In:Hagedorn CH, Rice CM, editors. The hepatitis C viruses. Berlin, Heidelberg:Springer Berlin Heidelberg; 2000. p. 149–169.
45. Shu-Hui C, Jason L, Yvonne Y, et al. P1 and P1; optimization of [3,4]-bicycloproline P2 incorporated tetrapeptidyl α-ketoamide based HCV protease inhibitors. Lett Drug Des Discov. 2005;2:118–123.
46. Saalau-Bethell SM, Woodhead AJ, Chessari G, et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol. 2012;8:920–925.
47. Xue W, Yang Y, Wang X, et al. Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein. Plos One. 2014;9:e87077.
48. Kaushik-Basu N, Bopda-Waffo A, Talele TT, et al. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res. 2008;36:1482–1496.
49. Beaulieu PL. CHAPTER 8 design and development of NS5B polymerase non-nucleoside inhibitors for the treatment of hepatitis C virus infection. In:Manoj C. Desai and Nicholas A. (eds). Successful strategies for the discovery of antiviral drugs:the royal society of chemistry. Cambridge UK:The Royal Society of Chemistry; 2013:248–294.
50. De Francesco R, Carfí A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Del Rev. 2007;59:1242–1262.
51. Bressanelli S, Tomei L, Rey FA, et al. Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides. J Virol. 2002;76:3482–3492.
52. Qin W, Luo H, Nomura T, et al. Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase. J Biol Chem. 2002;277:2132–2137.
53. Tellinghuisen TL, Rice CM. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002;5:419–427.
54. Lambert SM, Langley DR, Garnett JA, et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci. 2014;23:723–734.
55. Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist. 2014;7:41–56.
56. Elazar M, Cheong KH, Liu P, et al. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol. 2003;77:6055–6061.
57. Foster TL, Belyaeva T, Stonehouse NJ, et al. All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol. 2010;84:9267–9277.
58. Macdonald A, Crowder K, Street A, et al. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J Gen Virol. 2004;85:721–729.
59. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature. 2005;435:374–379.
60. Love RA, Brodsky O, Hickey MJ, et al. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol. 2009;83:4395–4403.
61. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100.• This article presents the first clinical validation of an HCV NS5A inhibitor, as an approach to suppress virus replication.
62. Azam SS, Abbasi SW, Batool M. Structure modeling and docking study of HCV NS5B-3a RNA polymerase for the identification of potent inhibitors. Med Chem Res. 2014;23:618–627.
63. Talele TT, Arora P, Kulkarni SS, et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Biorg Med Chem. 2010;18:4630–4638.
64. Li J, Liu X, Li S, et al. Identification of novel small molecules as inhibitors of hepatitis C virus by structure-based virtual screening. Int J Mol Sci. 2013;14:22845–22856.
65. Li X, Zhang W, Qiao X, et al. Prediction of binding for a kind of non-peptic HCV NS3 serine protease inhibitors from plants by molecular docking and MM-PBSA method. Biorg Med Chem. 2007;15:220–226.
66. Li W, Si H, Li Y, et al. 3D-QSAR and molecular docking studies on designing inhibitors of the hepatitis C virus NS5B polymerase. J Mol Struct. 2016;1117:227–239.
67. Subha K, Kumar GR, Rajalakshmi R, et al. a novel strategy for mechanism based computational drug discovery. Biomark Cancer. 2010;2:35–42.
68. Anwar-Mohamed A, Barakat KH, Bhat R, et al. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. Toxicol Lett. 2014;230:382–392.
69. Barakat KH, Anwar-Mohamed A, Tuszynski JA, et al. A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J Chem Inf Model. 2015;55:362–373.• This study is an example of how computational methods can be employed to reveal the binding mode of inhibitors. The study reports a ‘symmetric’ binding mode of daclatasvir, an HCV NS5A inhibitor.
70. Barakat KH, Jordheim LP, Perez-Pineiro R, et al. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. Plos One. 2012;7:e51329.
71. El-Labbad EM, Ismail MAH, Abou Ei Ella DA, et al. Discovery of novel peptidomimetics as irreversible CHIKV NsP2 protease inhibitors using quantum mechanical-based ligand descriptors. Chem Biol Drug Des. 2015;86:1518–1527.
72. Kalyaanamoorthy S, Chen Y-P-P. Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors. J Mol Graph Model. 2013;44:44–53.
73. Kalyaanamoorthy S, Chen Y-P-P. A steered molecular dynamics mediated hit discovery for histone deacetylases. Phys Chem Chem Phys. 2014;16:3777–3791.
74. Berger C, Romero-Brey I, Radujkovic D, et al. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology. 2014;147:1094–105.e25.
75. Ascher DB, Wielens J, Nero TL, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014;4:4765.
76. Ganesan A, Coote ML, Barakat K. Molecular dynamics-driven drug discovery:leaping forward with confidence. Drug Discov Today. 2017;22:249–269.
77. Ganesan A, Kumar RS, Kalyaanamoorthy S, et al. AIM-BLAST-AJAX interfaced multisequence blast. Proteomics Insights. 2009;2:9–13.
78. FFdC E, Karina SM, Teodorico CR. QSAR and docking studies of HCV NS3 serine protease inhibitors. Med Chem. 2013;9:774–805.
79. Ghasemi JB, Nazarshodeh E, Abedi H. Molecular docking, 2D and 3D-QSAR studies of new indole-based derivatives as HCV-NS5B polymerase inhibitors. J Iranian Chem Soc. 2015;12:1789–1799.
80. Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery:methods and applications. Nat Rev Drug Discov. 2004;3:935–949.• This article presents a detailed review on how docking-based scoring methods have been useful in virtual screening for drug discovery applications.
81. Yang S-Y. Pharmacophore modeling and applications in drug discovery:challenges and recent advances. Drug Discov Today. 2010;15:444–450.
82. Acharya C, Coop A, Polli JE, et al. Recent advances in ligand-based drug design:relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des. 2011;7:10–22.
83. Lewis RA, Wood D. Modern 2D QSAR for drug discovery. Wiley Interdiscip Rev Comput Mol Sci. 2014;4:505–522.
84. Clark M, Cramer RD, Jones DM, et al. Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases. Tetrahedron Comput Methodol. 1990;3:47–59.
85. Klebe G, Abraham U, Mietzner T. Molecular Similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem. 1994;37:4130–4146.
86. Rafiei H, Khanzadeh M, Mozaffari S, et al. QSAR study of HCV NS5B polymerase inhibitors using the genetic algorithm-multiple linear regression (GA-MLR). Excli J. 2016;15:38–53.
87. Elfiky AA, Elshemey WM. IDX-184 is a superior HCV direct-acting antiviral drug:a QSAR study. Med Chem Res. 2016;25:1005–1008.
88. Worachartcheewan A, Prachayasittikul V, Toropova AP, et al. Large-scale structure-activity relationship study of hepatitis C virus NS5B polymerase inhibition using SMILES-based descriptors. Mol Divers. 2015;19:955–964.
89. Chen J, Zhang L, Guo H, et al. Activity prediction of hepatitis C virus NS5B polymerase inhibitors of pyridazinone derivatives. Chemometrics Intellig Lab Syst. 2014;134:100–109.
90. Su L, Li L, Li Y, et al. Simple and accurate approaches to predict the activity of benzothiadiazine derivatives as HCV inhibitors. Med Chem Res. 2012;21:2079–2096.
91. Stachulski AV, Pidathala C, Row EC, et al. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J Med Chem. 2011;54:8670–8680.
92. Cheng Z, Zhang Y, Zhou C. QSAR Models for phosphoramidate prodrugs of 2′-methylcytidine as inhibitors of hepatitis C virus based on PSO boosting. Chem Biol Drug Des. 2011;78:948–959.
93. Michelle R, Marcus Tullius S, Mauro Vicentini C, et al. Sesquiterpene lactones with anti-hepatitis C virus activity using molecular descriptors. Lett Drug Des Discov. 2012;9:881–890.
94. Ke-Xian C, Hai-Ying X, Zu-Guang L. QSAR Analysis of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase. Acta Chim Slov. 2009;56:684–693.
95. Yu H, Fang Y, Lu X, et al. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors. Chem Biol Drug Des. 2014;83:89–105.
96. Jingyu Z, Youyong L, Huidong Y, et al. Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Comb Chem High Throughput Screen. 2012;15:439–450.
97. Wadood A, Riaz M, Uddin R, et al. In Silico Identification and Evaluation of Leads for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease Using Complex Based Pharmacophore Mapping and Virtual Screening. Plos One. 2014;9:e89109.
98. Wei Y, Li J, Qing J, et al. Discovery of novel hepatitis C virus NS5B polymerase inhibitors by combining random forest, multiple e-pharmacophore modeling and docking. Plos One. 2016;11:e0148181.
99. Svetnik V, Liaw A, Tong C, et al. Random Forest:A classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci. 2003;43:1947–1958.
100. Ahmed M, Pal A, Houghton M, et al. A comprehensive computational analysis for the binding modes of hepatitis C virus NS5A inhibitors:the question of symmetry. ACS Infect Dis. 2016;2:872–881.
101. Kerrigan J. Molecular dynamics simulations in drug design. In:Kortagere S, editor. In silico models for drug discovery. Methods in molecular biology. Vol. 993. Totowa, NJ:Humana Press; 2013. p. 95–113.
102. Tautermann CS, Seeliger D, Kriegl JM. What can we learn from molecular dynamics simulations for GPCR drug design? Comput Struct Biotechnol J. 2015;13:111–121.
103. Barakat K, Mane J, Friesen D, et al. Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions. J Mol Graph Model. 2010;28:555–568.
104. Barakat K, Tuszynski J. Relaxed complex scheme suggests novel inhibitors for the lyase activity of DNA polymerase beta. J Mol Graph Model. 2011;29:702–716.
105. Kalyaanamoorthy S, Chen Y-P-P. Modelling and enhanced molecular dynamics to steer structure-based drug discovery. Prog Biophys Mol Biol. 2014;114:123–136.
106. Hou T, Wang J, Li Y, et al. Assessing the Performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model. 2011;51:69–82.
107. Hou T, Wang J, Li Y, et al. Assessing the performance of the molecular mechanics/poisson boltzmann surface area and molecular mechanics/generalized born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem. 2011;32:866–877.
108. Xu L, Sun H, Li Y, et al. Assessing the Performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. J Phys Chem B. 2013;117:8408–8421.
109. Sun H, Li Y, Tian S, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys. 2014;16:16719–16729.
110. Sun H, Li Y, Shen M, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Phys Chem Chem Phys. 2014;16:22035–22045.
111. Hou T, Li N, Li Y, et al. Characterization of domain–peptide interaction interface:prediction of SH3 domain-mediated protein–protein interaction network in yeast by generic structure-based models. J Proteome Res. 2012;11:2982–2995.
112. Guan Y, Sun H, Li Y, et al. The competitive binding between inhibitors and substrates of HCV NS3/4A protease:A general mechanism of drug resistance. Antiviral Res. 2014;103:60–70.
113. Mortier J, Rakers C, Bermudez M, et al. The impact of molecular dynamics on drug design:applications for the characterization of ligand–macromolecule complexes. Drug Discov Today. 2015;20:686–702.
114. Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Biol. 2011;9:1–9.
115. Mahmoud AH, Elsayed MSA, ElHefnawi M. Structure-based predictive model for some benzimidazole inhibitors of hepatitis C virus NS5B polymerase. Med Chem Res. 2013;22:1866–1883.
116. Wu S, Kanda T, Nakamoto S, et al. Hepatitis C virus protease inhibitor-resistance mutations:our experience and review. World J Gastroenterol. 2013;19:8940–8948.
117. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192–206.
118. Lenz O, Verbinnen T, Lin T-I, et al. In Vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54:1878–1887.
119. Chen Z-W, Li H, Ren H, et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs):mining the genBank HCV genome data. Sci Rep. 2016;6:20310.
120. Guan Y, Sun H, Pan P, et al. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172:insight from molecular dynamics simulations and free energy calculations. Mol Biosyst. 2015;11:2568–2578.
121. Soumana DI, Kurt Yilmaz N, Ali A, et al. Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J Am Chem Soc. 2016;138:11850–11859.
122. Uengwetwanit T, Robaa D, Sippl W. Analysis of the resistance of hepatitis C virus NS5B polymerase inhibitors via docking and molecular dynamics simulation. Mol Inform. 2015;34:78–83.
123. Xue W, Pan D, Yang Y, et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Res. 2012;93:126–137.
124. Kramer M, Halleran D, Rahman M, et al. Comparative molecular dynamics simulation of hepatitis C virus NS3/4A protease (Genotypes 1b, 3a and 4a) predicts conformational instability of the catalytic triad in drug resistant strains. Plos One. 2014;9:e104425.
125. Xue W, Jiao P, Liu H, et al. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598. Antiviral Res. 2014;104:40–51.
126. Wang H, Cui W, Guo C, et al. Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055. Biochem Cell Biol. 2015;94:147–158.
127. Elfiky AA, Elshemey WM, Gawad WA, et al. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 2013;32:75–80.
128. De Vivo M, Masetti M, Bottegoni G, et al. role of molecular dynamics and related methods in drug discovery. J Med Chem. 2016;59:4035–4061.
129. Bernardi RC, Melo MCR, Schulten K. Enhanced sampling techniques in molecular dynamics simulations of biological systems. Biochim Biophys Acta. 2015;1850:872–877.
130. Rodriguez-Bussey IG, Doshi U, Hamelberg D. Enhanced molecular dynamics sampling of drug target conformations. Biopolymers. 2016;105:35–42.
131. Warshel A, Levitt M. Theoretical studies of enzymic reactions:dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme. J Mol Biol. 1976;103:227–249.
132. Ganesan A, Dreyer J, Wang F, et al. Density functional study of Cu2+-phenylalanine complex under micro-solvation environment. J Mol Graph Model. 2013;45:180–191.
133. Park S, Schulten K. Calculating potentials of mean force from steered molecular dynamics simulations. J Chem Phys. 2004;120:5946–5961.
134. Pan D, Niu Y, Ning L, et al. Computational study on the binding and unbinding mechanism of HCV NS5B with the inhibitor GS-461203 and substrate using conventional and steered molecular dynamics simulations. Chemometrics Intellig Lab Syst. 2016;156:72–80.
135. Pan D, Niu Y, Xue W, et al. Computational study on the drug resistance mechanism of hepatitis C virus NS5B RNA-dependent RNA polymerase mutants to BMS-791325 by molecular dynamics simulation and binding free energy calculations. Chemometrics Intellig Lab Syst. 2016;154:185–193.
136. Pinheiro AS, Duarte JBC, Alves CN, et al. Virtual screening and molecular dynamics simulations from a bank of molecules of the amazon region against functional NS3-4A protease-helicase enzyme of hepatitis C virus. Appl Biochem Biotechnol. 2015;176:1709–1721.
137. Parks JM, Kondru RK, Hu H, et al. Hepatitis C virus NS5B polymerase:QM/MM calculations show the important role of the internal energy in ligand binding. J Phys Chem B. 2008;112:3168–3176.
138. Zeisel MB, Crouchet E, Baumert TF, et al. Host-targeting agents to prevent and cure hepatitis C virus infection. Viruses. 2015;7:5659–5685.
139. Fazi R, Tintori C, Brai A, et al. Homology model-based virtual screening for the identification of human helicase DDX3 inhibitors. J Chem Inf Model. 2015;55:2443–2454.
140. Yang S, J KR, Lim S, et al. Structure-based discovery of novel cyclophilin A inhibitors for the treatment of hepatitis C virus Infections. J Med Chem. 2015;58:9546–9561.
141. Henriksen NM, Hayatshahi HS, Davis DR, et al. Structural and energetic analysis of 2-aminobenzimidazole inhibitors in complex with the hepatitis C virus IRES RNA using molecular dynamics simulations. J Chem Inf Model. 2014;54:1758–1772.
142. Golebiowski J, Antonczak S, Di-Giorgio A, et al. Molecular dynamics simulation of hepatitis C virus IRES IIId domain:structural behavior, electrostatic and energetic analysis. J Mol Model. 2004;10:60–68.
143. Pérard J, Leyrat C, Baudin F, et al. Structure of the full-length HCV IRES in solution. Nat Commun. 2013;4:1612.
144. Saunders MG, Voth GA. Coarse-graining methods for computational biology. Annu Rev Biophys. 2013;42:73–93.